CD274 and non-small cell lung carcinoma: Atezolizumab is also another ICIC that targets the programmed death-ligand 1 (PD-L1) checkpoint and is approved for the treatment of bladder cancer, non-small cell lung cancer, and triple-negative breast cancer, among others.